Dr. Axel Mescheder
Dr. Axel Mescheder has a successful track record of more than 30 years in the pharmaceutical, CRO and biotechnology industry. Prior to joining Berlin Cures, he held various senior management and C-level positions at SynOx Therapeutics, Medpace and TopoTarget and was responsible for several clinical development programs leading to successful product registrations or label extensions in both Europe and the United States.
Dr. Mescheder is a board-certified M.D. from the University of Kiel (Germany), with a medical license and full specialization in Pharmacology and Toxicology. At Berlin Cures, Dr. Mescheder is responsible for the clinical development of BC 007.
